"Metabolomics for Pharmaceutical Applications - Vol 2" showcases the impact of metabolomics in advancing drug development and precision medicine. Key highlights include studies on the safety of inhaled glucocorticoids for asthma, the link between pollution exposure and skin diseases, and metabolic signatures for obesity. Additionally, it identifies salivary biomarkers for periodontal disease and diabetes, and novel biomarkers to optimize busulfan dosing in cancer treatment. These case studies demonstrate how metabolomics provides critical insights into disease mechanisms, enabling more precise treatment strategies and improved clinical trial outcomes.

Join for free to read